Phase
Condition
Diabetic Vitreous Hemorrhage
Diabetic Retinopathy
Diabetic Neuropathy
Treatment
Dexcom CGM G6/G6 Pro/G7
Clinical Study ID
Ages > 2 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
Has at least one HbA1C (Hemoglobin a1c) measurement within three (3) months prior tothe Dexcom CGM System use start date that is at least three (3) months after anyprior CGM use
Subject is willing and able to use Dexcom CGM System according to approved productlabeling
Subject is willing and able to complete applicable patient reported outcomeassessments/ surveys
Subject is willing and able to comply with the protocol
Subject is willing and able to comply with provider requirements for at least twoprovider encounters per year according to applicable clinical practice guidelines
Subject or the subject's legally authorized representative must provide writteninformed consent prior to any study-related data collection or be enrolled under anIRB/EC approved waiver of consent
Exclusion
Exclusion Criteria:
Is contraindicated for a Dexcom CGM System per approved commercial labeling
In the Investigator's opinion, the subject is not considered to be a suitablecandidate
Study Design
Study Description
Connect with a study center
Institute of Endocrinology Diabetes, Health & Hormones
Stockbridge, Georgia 30281
United StatesActive - Recruiting
Palm Research Center
Las Vegas, Nevada 89148
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.